NLS Pharmaceutics (NLS Pharmaceutics) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NLS Pharmaceutics's EBITDA for the six months ended in Dec. 2023 was $-4.41 Mil. NLS Pharmaceutics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, NLS Pharmaceutics's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

NLS Pharmaceutics EBITDA Margin % Historical Data

The historical data trend for NLS Pharmaceutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics EBITDA Margin % Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of NLS Pharmaceutics's EBITDA Margin %

For the Biotechnology subindustry, NLS Pharmaceutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's EBITDA Margin % falls into.

NLS Pharmaceutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NLS Pharmaceutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-12.015	/	0
	=	%

NLS Pharmaceutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.409	/	0
	=	%

NLS Pharmaceutics (NAS:NLSP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

NLS Pharmaceutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.